|
KMID : 0882420230980060283
|
|
Korean Journal of Medicine
2023 Volume.98 No. 6 p.283 ~ p.288
|
|
|
Hormone Treatment for Breast Cancer
|
|
Lee Su-Ee
|
|
|
Abstract
|
|
|
|
Hormone receptor-positive breast cancer accounts for 60-70% of all breast cancers and has a better prognosis than human epidermal growth factor receptor-2 (HER2)-positive or triple-negative breast cancer. Hormone treatment for breast cancer is an important treatment method that is effective and has few side effects for hormone receptor-positive breast cancer. Hormone therapy is performed as adjuvant therapy in early breast cancer and as palliative therapy in metastatic breast cancer. In the past decade, molecularly targeted agents against intracellular targets such as mammalian target of rapamycin (everolimus), cyclin-dependent kinase 4 and 6 (palbociclib, ribociclib, abemaciclib), and phosphatidylinositol 3-kinase (alpelisib) has offered patients effective therapeutic options, and combination of hormone treatment with the molecular agents have continued to improve the outcome of breast cancer.
|
|
|
KEYWORD
|
|
|
Breast neoplasms, Antineoplastic agents, hormonal, CDK 4/6 inhibitor
|
|
|
FullTexts / Linksout information
|
|
|
|
|
Listed journal information
|
|
|
|